Schubert & CO Harmony Biosciences Holdings, Inc. Transaction History

Schubert & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 02, 2023	SELL	$30.8 - $53.92 $308 - $539	-10 Reduced 40.0%	15 $0
Q4 2022 Jan 31, 2023	BUY	$45.4 - $60.91 $408 - $548	9 Added 56.25%	25 $1,000
Q3 2022 Oct 21, 2022	BUY	$42.06 - $55.45 $42 - $55	1 Added 6.67%	16 $1,000
Q2 2022 Aug 01, 2022	BUY	$33.54 - $52.15 $368 - $573	11 Added 275.0%	15 $1,000
Q1 2022 May 16, 2022	BUY	$33.14 - $51.13 $99 - $153	3 Added 300.0%	4 $0
Q4 2021 Jan 28, 2022	BUY	$34.09 - $43.91 $34 - $43	1 New	1 $0

254

46.6M

119K

50K

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.02B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

Get notified when there are updates to the investment portfolio of Schubert & CO, based on Form 13F filings with the SEC.

Stay updated on Schubert & CO with notifications on news.